Engineering naturally occurring CD7- T cells for the immunotherapy of hematological malignancies

Chimeric antigen receptor (CAR) T-cell therapy targeting T-cell acute lymphoblastic leukemia (T-ALL) faces limitations such as antigen selection and limited T-cell persistence. CD7 is an attractive antigen for targeting T-ALL, but overlapping expression on healthy T cells leads to fratricide of CD7-CAR T cells, requiring additional genetic modification. We took advantage of naturally occurring CD7(-) T cells to generate CD7-CAR (CD7-CAR(CD7-)) T cells. CD7-CAR(CD7-) T cells exhibited a predominantly CD4(+) memory phenotype and had significant antitumor activity upon chronic antigen exposure in vitro and in xenograft mouse models. Based on these encouraging results, we next explored the utility of CD7(-) T cells for the immunotherapy of CD19(+) hematological malignancies. Direct comparison of nonselected (bulk) CD19-CAR and CD19-CAR(CD7-) T cells revealed that CD19-CAR(CD7-) T cells had enhanced antitumor activity compared with their bulk counterparts in vitro and in vivo. Lastly, to gain insight into the behavior of CD19-CAR T cells with low levels of CD7 gene expression (CD7(lo)) in humans, we mined single-cell gene and T-cell receptor (TCR) expression data sets from our institutional CD19-CAR T-cell clinical study. CD19-CAR(CD7lo) T cells were present in the initial CD19-CAR T-cell product and could be detected postinfusion. Intriguingly, the only functional CD4(+) CD19-CAR T-cell cluster observed post infusion exhibited CD7(lo) expression. Additionally, samples from patients responsive to therapy had a higher proportion of CD7(lo) T cells than nonresponders (NCT03573700). Thus, CAR(CD7-) T cells have favorable biological characteristics and may present a promising T-cell subset for adoptive cell therapy of T-ALL and other hematological malignancies.

Automated summary

CD7(-) T cells can serve as a promising subset for CAR-T cell therapy of T-ALL and other hematological malignancies.